We are IntechOpen,
the world's leading publisher of
Open Access books
Built by scientists, for scientists

4,800
Open access books available

122,000
International authors and editors

135M
Downloads

Our authors are among the

154
Countries delivered to

TOP 1%
most cited scientists

12.2%
Contributors from top 500 universities

CLARIVATE ANALYTICS

BOOK CITATION INDEX

INDEXED

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Endoscopic Retrograde Cholangiopancreatography-Related Acute Pancreatitis – Identification, Prophylaxis and Treatment

Alejandro González-Ojeda[1], Carlos Dávalos-Cobian[2],
Elizabeth Andalón-Dueñas[1], Mariana Chávez-Tostado[1],
Arturo Espinosa-Partida[1] and Clotilde Fuentes-Orozco[1]
[1]Surgical Section of the Research Unit in Clinical Epidemiology,
Specialties Hospital, Western Medical Center,
Mexican Institute of Social Security, Guadalajara, Jalisco,
[2]Department of Gastroenterology and Gastrointestinal Endoscopy,
Specialties Hospital, Western Medical Center,
Mexican Institute of Social Security, Guadalajara, Jalisco,
Mexico

1. Introduction

Pancreatitis is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP) [1–4]. The reported incidence ranges from 1.8% to 7.2% in most prospective series [5–9] but can be up to 30%, depending on the criteria used to diagnose pancreatitis, the type and duration of patient follow-up, and the type of case mix [10]. More commonly, hyperamylasemia occurs in up to 30% of patients undergoing ERCP [11].

As the indications for ERCP have increased, a greater focus on recognizing and preventing complications has emerged. The recognized complications of ERCP include asymptomatic hyperamylasemia, cardiopulmonary depression, hypoxia, aspiration, intestinal perforation, bleeding, cholangitis, adverse medication reactions, sepsis, acute pancreatitis, and death. Post-ERCP pancreatitis (PEP) remains the leading cause of morbidity and mortality after the procedure and is the focus of studies designed to improve procedural outcomes [12,13]. Some studies have suggested that the rates of PEP can be reduced, but the incidence of pancreatitis remains high particularly in at-risk patient populations. Pancreatitis continues to be the major cause of postprocedure morbidity and mortality [14–17].

2. Diagnosis of PEP

PEP was defined initially as the presence of new pancreatic-type abdominal pain associated with at least a threefold increase in serum amylase concentration occurring 24 h after an ERCP, with pain severe enough to require admission to the hospital or to extend an

admitted patient's length of stay. This definition was developed in 1991 based upon approximately 15 000 procedures evaluated during a consensus workshop. The severity of PEP was defined according to the length of stay (mild pancreatitis 2–3 d, moderate pancreatitis 4–10 d, and severe pancreatitis >10 d, or intensive care admission or local complications secondary to pancreatitis) [18]. This consensus definition has not been adopted uniformly and many studies published after 1991 have used different criteria to define PEP and to classify its severity. Several studies have challenged the serum amylase threshold of three times the upper limit of normal, arguing that this definition is not always consistent with the clinical and morphological features of pancreatitis [19–25]. Other criteria for serum amylase elevation include twice [23–26], four times [6,27,28] and five times [20,21,28–30] the upper normal limit.

There is also heterogeneity in the criteria used to classify the severity of PEP in published studies. Some authors have used the Atlanta criteria published in 1993 to define severity [31–33]. The Atlanta criteria incorporate systemic complications of PEP by integrating the Acute Physiologic and Chronic Health Evaluation (APACHE) II classification and Ranson's criteria to define the severity [33–35]. An APACHE II score of >8 or a Ranson's score of ≥3 of 11 criteria are defined as severe PEP. Some studies have used the APACHE II classification alone to grade the severity of PEP [36]. Other studies have used combinations of criteria to define the presence and severity of PEP or have established unique definitions [26,31,37–40]. The heterogeneity of criteria in the literature on PEP hinders direct comparison of the published clinical trials.

3. Pathophysiology of PEP

The pathophysiology of PEP is not well understood. Mechanical, hydrostatic, chemical, enzymatic, allergic, thermal, cytokine, oxidative, and microbiological factors have all been proposed as causes [32,41–46]. Many studies suggest that PEP results from mechanical trauma, causing injury to the papilla or pancreatic sphincter and subsequent swelling of the pancreatic duct and obstruction to the flow of pancreatic enzymes. This hypothesis remains controversial, and no consensus about the pathogenesis of PEP has been established.

The cascade of events leading to acute pancreatitis is characterized by three phases. The first phase is characterized by premature activation of trypsin within the pancreatic acinar cells [47]. The second phase is characterized by intrapancreatic inflammation. The third phase is characterized by extrapancreatic inflammation [47]. Inflammation in the second and third phases has been described as a four-step process: (1) activation of inflammatory cells; (2) chemoattraction of activated inflammatory cells; (3) activation of adhesion molecules causing binding of inflammatory cells to the endothelium; and (4) migration of activated inflammatory cells into areas of inflammation [47]. Recent studies have evaluated proinflammatory markers (TNF, interleukin-1 (IL-1), IL-6, IL-8, PAF, and IL-10) in the setting of PEP [48–51]. Although three randomized controlled trials (RCTs) suggested a protective effect of low- or high-dose (4 μg/kg or 20 μg/kg) IL-10 given intravenously 15–30 min before ERCP [52], subsequent studies using similar IL-10 protocols did not support these findings [53,54]. Although not demonstrated at present, modulation of proinflammatory pathways might be an appealing goal for studies evaluating PEP and the systemic inflammatory response.

4. Procedural-related factors associates with PEP

Although the triggers of the inflammatory cascade are not well understood, procedural- and patient-related factors have been clearly associated with the incidence of PEP. ERCP is the most technically difficult endoscopic procedure performed by trainees and experienced endoscopists in both inpatient and outpatient settings. Whereas trauma to the duodenum or papilla during endoscopy without cannulation rarely causes pancreatitis [55], cannulation of the papilla, especially in moderate to difficult cases, is associated with high rates of PEP. Procedures involving multiple (>1–4) or failed attempts at cannulation, multiple pancreatic injections ($\geq$2–5), pancreatic acinarization, and prolonged cannulation time (>10 min) are associated with PEP. The following factors have also been associated with a higher risk for developing PEP: operator experience, ampullary balloon dilation, precut access sphincterotomy, endoscopic sphincterotomy (ES), sphincter of Oddi manometry, distal common bile duct diameters of $\leq$1 cm, presence of a pancreatic stricture, papillectomy, and procedures not involving stone removal [45,56–59] (Table 1).

Patient related factors	Young age. Female gender. Suspected sphincter of Oddi dysfunction. Recurrent pancreatitis. Prior history of post-ERCP pancreatitis. Patients with normal serum bilirubin.
Procedure related factors	Multiple pancreatic duct injections. Difficult cannulation. Pancreatic sphincterotomy. Precut access. Balloon dilation.
Operator/technical related factors	Inadequate training and/or experience
	Trainee involvement in procedure

Table 1. Factors Increasing the Risk of Post-ERCP Pancreatitis.

4.1 Operator experience

Although there is no established mandate for the procedure volume to develop competence in ERCP, a prospective study published in 1996 evaluated the number of supervised ERCPs a physician must perform to achieve procedural competence and reported that at least 180 procedures are required [60]. In the United States, the American Society for Gastrointestinal Endoscopy and the American College of Gastroenterology have published quality indicators for ERCP. Competent endoscopists are expected to be able to perform sphincterotomy, clear the common bile duct of stones, provide relief of biliary obstruction, and successfully place stents for bile leaks in $\geq$85% of patients [61].

Few studies have been published on operator experience in ERCP, and this issue remains controversial. A recent study in Austria showed that a case volume of >50 ERCPs per year had higher success and lower overall complication rates [62]. It is generally agreed that the case mix at high volume and in academic referral centers may include a larger proportion of

difficult and high-risk cases, which may confound the relationship between experience and complication rates. Although operator experience is felt to be critical for high-quality outcomes, many large prospective and retrospective trials have not shown consistent correlations between inexperience and PEP. Higher rates of bleeding have been reported after endoscopic sphincterotomy with a mean case volume of <1 per wk [14], and trainee involvement was associated with severe or fatal complications in a recent retrospective analysis [63]. However, a large prospective trial found that case volume had no effect on the incidence of PEP [24]. A prospective study of ERCP in the United Kingdom (UK) in 2007 based on self-reported surveys demonstrated that 15% of all credentialed endoscopists performed <50 ERCPs per year compared with 61% of those in training; 11% of deaths occurred after procedures by endoscopists who performed <50 ERCPs per year. Although the rates of PEP were low at 1.5%, the success rates for bile duct stone extraction and biliary stent placement were 62% and 73%, respectively. The authors concluded that in the UK there is a need for fewer operators and greater experience in those performing therapeutic endoscopy [64]. In the same year, a study in France showed no risk associated with operator inexperience [65].

4.2 Cannulation techniques

Cannulation techniques to access the pancreatic and biliary ducts include the use of a sphincterotome or straight or curved catheter with guide wires or contrast injection. When an initial attempt at cannulation fails, access may be achieved after placement of a pancreatic guide wire or stent to help guide the endoscopist toward the common bile duct and away from the pancreatic duct. Precut access papillotomy is used frequently in referral centers when conventional approaches fail. Rare or experimental techniques such as the use of endoscopic scissors or endoscopic dissection with a cotton swab have been reported but are used rarely in clinical practice [66].

Compared with a standard catheter, the use of a sphincterotome may decrease the number of failed attempts to obtain biliary access, the time required to cannulate the common bile duct, and the rate of PEP [67,68]. Selective sphincterotome cannulation with a guide wire may reduce the rate of PEP compared with cannulation with contrast injection [67–71]. In 2008, a large prospective controlled trial randomized 430 patients into sphincterotome plus guide wire versus conventional cannulation arms. The series demonstrated a significantly higher rate of cannulation with guide wires but failed to show a significant difference in the rate of PEP between the two approaches [72]. The authors reported an 8.8%–14.9% increased risk of PEP after >4 attempts at the papilla, highlighting the importance of cannulation with fewer attempts. These findings are consistent with those of previous studies [7,72].

4.3 Pancreatic duct injection

Multiple pancreatic duct injections (≥2–5) [6,7,15,24,58] and pancreatic acinarization [6,12,15,30] are recognized as risk factors for PEP. Differences in the osmolality and ionicity of contrast media have been studied with varying results in terms of impact on PEP [25,28,59,73–75]. A recent meta-analysis of 13 RCTs found no significant difference between high- and low-osmolality contrast media [75]. Earlier studies suggested that there is a decreased risk of PEP with the use of nonionic contrast agents [73], although this has not been demonstrated consistently [74]. One large retrospective analysis of 14 331 ERCPs suggested that less opacification of the pancreatic duct in the head than in the tail produced

significantly lower rates of PEP [59]. Despite the variable findings, clinical trial data suggest that hydrostatic pressure may play a role in the development of pancreatitis.

4.4 Pancreatic duct stenting

The theory that PEP is caused by pancreatic duct obstruction is supported by most RCTs, which show a decreased incidence of pancreatitis in high-risk patients after placement of a pancreatic duct stent [76–84]. The three largest published studies to evaluate the rate of pancreatitis with pancreatic duct stent placement reported significant decreases, by 10.4%, 14.8%, and 52.3%, in the rates of PEP in patients treated with stent placement versus those without stent placement [78,79,85]. Although pancreatic duct stenting decreases the risk of PEP, it has not been shown to prevent it. Despite stent placement, pancreatitis occurs in 2.0%–14% of patients [78,79,81,83,84], and some studies have failed to demonstrate a significant protective effect [59,83,84]. Eight RCTs, multiple prospective uncontrolled studies, and five meta-analyses have compared the rates of pancreatitis after ERCP with and without prophylactic pancreatic stent placement [86–90]. Prophylactic stent placement reduces the incidence of PEP, particularly in high-risk patients, and virtually eliminates the risk of severe pancreatitis.

Many studies have criticized the absence of intent-to-treat analysis (i.e., patients with attempted but unsuccessful stent placement were excluded). However, a meta-analysis showed that the four RCTs used intent-to-treat principles by assuming that PEP developed in patients in whom the attempted prophylactic pancreatic stent placement failed, even when the clinical outcome was not stated in the original study. Despite the use of this approach, the odds ratio in the stent group was 0.44 compared with the controls and differed significantly in favor of stent placement [86]. On the basis of these results, prophylactic stent placement can be considered as the single most important advance in the past 15 years for the prevention of PEP in high-risk patients. Despite these findings, questions remain about when to place a prophylactic pancreatic stent, the type of stent to place, and the optimal follow-up period to ensure adequate removal. The incidence of adverse events associated with pancreatic stent placement is around 4% and must be considered in the decision-making process for the placement of a stent [86,91].

4.5 Biliary stone extraction

In the setting of choledocholithiasis, endoscopic papillary balloon dilatation (EPBD), ES, and mechanical lithotripsy are techniques used to extract obstructing stones. Many studies have shown an increased rate of PEP with EPBD; the rates range from 4.9–20% with EPBD versus 0.42–10% with ES [92–95]. Prospective trials support this observation, although it is difficult to generalize the findings given the many factors that contribute to procedural complications [96–100]. Balloon dilation may also be required in some clinical settings. If a patient has had a prior sphincterotomy and has limited remaining tissue for incision, balloon dilation may be necessary to enlarge the bile duct insertion and enable stone extraction.

5. Patient-related risk factors associated with PEP

Given the high risk of PEP in certain populations, identifying a clear indication is critical for reducing the complication rate. ERCP is riskiest in patients who need it the least [101,102].

Large prospective trials have demonstrated that being female, being younger than 60–70 years, and having suspected sphincter of Oddi dysfunction (SOD) or a recurrent or prior PEP are associated with a higher risk of PEP [6,9,15,24,45,87,103,104] (Table 1). However, there is some variability between studies. For example, one smaller trial suggested an age of <50 years as a significant risk factor [104]. A recent large retrospective study of 16 855 patients reported that the highest rates of PEP occurred in patients with SOD, but the rate was not significantly higher in younger patients or in women [63]. Alternatively, a meta-analysis evaluating five patient-related risk factors demonstrated relative risks of SOD of 4.09 (95% CI, 1.93–3.12; P<0.001) and of being female of 2.23 (95% CI, 1.75–2.84; P<0.001) [87]. One study demonstrated a 10-fold increase in the risk of PEP in patients with SOD [105]. Some factors may be protective as well. The absence of chronic pancreatitis [57], presence of obesity [106], older age (>80 years) [107], and a history of alcohol consumption or cigarette smoking may be associated with a lower risk of PEP [108]. Proper patient selection and identification of patients at higher risk are the most effective means for reducing the incidence of PEP.

6. Pharmacological agents evaluated for the prevention or reduction of PEP

The effects of pharmacological agents on PEP have attracted much interest. Preventing cellular injury and pancreatic tissue auto-digestion may involve blocking the premature activation of proteolytic enzymes within the acinar cells [14,45,109–116]. Although conceptually straightforward, the goal of blocking this activation has been difficult to achieve. Multiple trials have been performed with the goal of reducing the incidence or severity of PEP. About 34 pharmacological agents and procedures (e.g., topical application of pharmacological agents injected or sprayed onto the papilla) have been evaluated for their potential to prevent PEP in controlled trials. Most clinical trials have been disappointing, and only a minority of studies has demonstrated benefit (Table 2-5) [26,29,37,39,40,53,54,58,87,117–175].

In two of five prospective trials, allopurinol was shown to decrease the incidence of PEP [119,120]. In these trials showing benefits, allopurinol was given in 300 mg or 600 mg doses 15 h and 3 h before ERCP. When reviewing other studies of allopurinol, these effects were not significant in patients dosed on different 4 h and 1 h regimens and with varying dose concentrations of allopurinol [121–123]. This suggests that both the dose and timing of allopurinol administration are important in reducing the risk of PEP.

Three meta-analyses have been published using data obtained from four prospective, randomized, placebo-controlled studies that compared rectally administered diclofenac or indomethacin at a dose of 100 mg versus placebo [124–126]. No statistical heterogeneity was detected between the studies. Two RCTs evaluated the effect of rectal administration of 100 mg diclofenac immediately after the procedure [39,143], and the other two evaluated rectal administration of 100 mg indomethacin immediately before the procedure [144,145]. Both sets of studies showed similar results. Patients who were considered to be at high risk for PEP were included in both studies. Overall, PEP occurred in 20/456 (4.4%) patients in the treatment groups versus 57/456 (12.5%) patients in the placebo groups. The estimated pooled relative risk was 0.36 (95% CI, 0.22–0.60), and the number needed to treat to prevent one episode of PEP was 15. The administration of nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with a similar decrease in the incidence of PEP regardless of risk. No adverse event attributable to NSAIDs has been reported. A trial evaluating diclofenac 50

Agent	Author	Factor studied	n	Rate of post-ERCP pancreatitis (%)			P value
				Overall	Control	Intervention	
STEROIDS							
Hydrocortisone							
	Kwanngern[130]	Hydrocortisone 100 mg IV at 1 h before ERCP	120	6.67	11.86	1.64	0.031
	Manolakopoulos[131] MC	Hydrocortisone 100 mg IV at 30 min before ERCP	340	10.00	13.00	7.10	0.380
	De Palma[26]	Hydrocortisone 100 mg IV immediately before ERCP	529	5.30	4.90	5.70	NS
Prednisone							
	Sherman[132] MC	Prednisone 40 mg PO at 15 h and at 3 h before ERCP	1115	15.07	13.60	16.60	0.190
	Budzyńska[123]	Prednisone 40 mg at 15 h; 40 mg at 3 h before ERCP		10.70	7.90	12.00	0.330
Methylprednisolone							
	Dumot[118]	Methylprednisolone 125 mg IV immediately before ERCP	286	NR	8.70	12.40	0.340
NSAID's							
Diclofenac							
	Khoshbaten[143]	Diclofenac 100 mg PR immediately after ERCP	100	15.00	26.00	4.00	< 0.010
	Cheon[146]	Diclofenac 50 mg PO at 30-90 min before and at 4-6 h after ERCP	207	16.40	16.70	16.20	NS
	Murray[39]	Diclofenac 100 mg PR immediately after ERCP	220	11.00	15.45	6.36	0.049
	Senol[147]	Diclofenac 75 mg IV immediately after ERCP	80	12.5	17.5	7.5	0.176
Indomethacin							
	Sotoudehmanesh[145]	Indomethacin 100 mg PR before ERCP	442	4.98	6.78	3.16	OR 0.4 (0.2 - 1.1)
	Montaño-Loza[144]	Indomethacin 100 mr PR before ERCP	150	10.6	16	5.3	0.034
ANTIOXIDANTS							
Allopurinol							
	Martinez-Torres[119]	Allopurinol 300 mg PO at 15 h; 300 mg PO at 3 h before ERCP	170	6.47	9.40	2.30	0.049
	Romagnuolo[121] MC	Allopurinol 300 mg PO at 1 h before ERCP	586	NR	4.10	5.50	0.440
	Katsinelos[120]	Allopurinol 600 mg PO at 15 h; 600 mg PO at 3 h before ERCP	243	10.20	17.80	3.20	< 0.001
	Mosler[122]	Allopurinol 600 mg PO at 4 h; 300 mg PO at 1 h before ERCP	346	12.55	12.14	12.96	0.520
	Budzynska[123]	Allopurinol 200 mg PO at 15 h; 200 mg PO at 3 h before ERCP	300	10.70	7.90	12.10	0.320
ANTIBIOTICS							
N-acetylcystine							
	Milewski[134]	NAC 600 mg IV BID × 2 d after ERCP	106	9.43	11.76	7.27	NS
	Katsinelos[135]	NAC 70 mg/kg 2 h before and 35 mg/kg 4 h intervals for 24 h after procedure	249	10.80	9.60	12.10	> 0.500
Cephtazidime							
	Räty[129]	Cephtazidime 2g IV 30 min before ERCP	321	NR	9.38	2.58	0.009
INTERLEUKIN-10							
Interlukin-10							
	Sherman[54]MC	IL-10 8 μg/kg IV 15-30 min before ERCP	305	17.38	14.30	15.40	0.830
		IL-10 20 μg/kg IV 15-30 min before ERCP			22.00		0.140
	Devière[52]	IL-10 4 μg/kg IV 30 min before ERCP	144	29.90	24.40	10.41	0.046
		IL-10 20 μg/kg IV 30 min before ERCP				6.81	0.017
	Dumot[53]	IL-10 8 μg/kg IV 15 min before ERCP	200	10.00	9.10	10.90	0.650

PEP: Post-ERCP pancreatitis; ERCP: Endoscopic retrograde cholangiopancreatography; IL-10: Ingerlukin-10; NAC: N-acetyl cystine; NS: Not significant; NR: Not reported/unable to acquire primary data from publication; MC: Multi-centered.

Table 2. Randomized controlled trails of drugs that decrease inflammation evaluated for reduction or prevention of post-ERCP pancreatitis.

| Agent | Author | Factor studied | Rate of post-ERCP pancreatitis (%) | | | | |
			n	Overall	Control	Intervention	P value
Heparin							
	Barkay[37]	Unfractionated heparin 5000 IU SC 20-30 min before ERCP	106	NR	7.40	7.80	NS
	Rabenstein[133]	Low molecular weight heparin Certoparin 3000 IU SC the day before ERCP	448	8.50	8.81	8.14	0.870
Gabexate							
	Ueki[159]	Gabexate 600 mg IV 60-90 min before and 22 h after ERCP	68	2.90	NR	2.90	NS
	Manes[160]MC	Gabexate mesylate 500 mg within 1 h before ERCP	608	5.60	9.40	3.90	< 0.01
		Gabexate mesylate 500 mg within 1h after ERCP				3.40	< 0.01
	Xiong[161]	Gabexate 300 mg IV 30 min before gtt until 4 h after ERCP	200	6.70	10.50	3.10	0.04
	Fujishiro[162]	Gabexate 900 mg/1500 mL gtt for 13 h beginning 1 h before ERCP	139	NR	NRa	4.30	NS
	Andriulli[163]MC	Gabexate 500 mg 30 min before gtt until 6 h after ERCP	1127	5.60	4.80	5.80	NS
	Masci[87]MC	Gabexate 500 mg IV 30 min before gtt until 6.5 h after ERCP and 1 g IV for 13 h after ERCP	434	1.80	2.20	1.40	NS
	Andriulli[163]MC	Gabexate 500 mg IV 30 min before and 2 h after ERCP	579	8.60	6.50	8.10	NS
	Cavallini[164]MC	Gabexate 1 g IV 30-90 min before gtt until 12 h after ERCP	418	5.00	8.00	2.00	0.03
Ulinastatin							
	Yoo[166]	Ulinastatin 100 000 U gtt after ERCP for 5.5 h	227	6.20	5.60	6.70	0.715
	Ueki[159]	Ulinastatin 150 000 units 60-90 min before & for 22 h after ERCP	68	2.90	2.90	2.90	NS
	Fujishiro[162]MC	Ulinastatin 150 000 units 1 h before, during; 11 h after ERCP				6.50	NS
		Ulinastatin 50 000 units				8.50	NS
	Tsujino[167]MC	Ulinastatin 150 000 U gtt 10 min before ERCP	406	5.17	7.40	2.90	0.041

PEP: Post-ERCP pancreatitis; ERCP: Endoscopic retrograde cholangiopancreatography; NS: Not significant;NR: Not reported/unable to acquire primary data from publication; MC: Multi-centered.

Table 3. Randomized controlled trails of drugs that interrupt the activity of proteases evaluated for reduction or prevention of post-ERCP pancreatitis.

Agent	Author	Factor studied	Rate of post-ERCP pancreatitis (%)				
			n	Overall	Control	Intervention	P value
Beta-carotene							
	Lavy[127]	Natural beta-carotene 2 g at 12 h before ERCP	321	9.60	9.60	10.00	NR
Octreotide							
	Kisli[149]	Octreotide 0.1 mg gtt 60 min before ERCP and continued during and after ERCP	120	NR	11.49	15.15	NS
	Li[150]	Octreotide 0.3 mg gtt 1 h before -6 h after ERCP; then 0.1 mg SC; 12 h later 0.1 mg SC	832	3.85	5.26	2.42	0.046
	Thomopoulos[151]	Octreotide 500 µg TID starting 24 h before ERCP	201	10.89	8.90	2.00	0.03
	Testoni[152]	Octreotide 200 µg TID × 24 h before ERCP	114	NR	14.30	12.00	NS
	Hardt[153]	Octreotide 200 µg SC the night before ERCP	94	NR	NR	NR	NS
	Duvnjak[154]	Octreotide 0.5 mg SC 60 min before ERCP	209	NR	9.52	3.85	NS
	Arvanitidis[155]	Octreotide 0.1 mg SC 30 min before; 8 h and 16 h after ERCP	73	10.95	11.11	10.81	NS
	Tulassay[40]	Octreotide 0.1 mg SC 45 min after ERCP	1199	7.84	6.00	5.90	NS
	Arcidiacono[156]	Octreotide 0.1 mg SC 120 and 30 min before; 4 h after ERCP	151	6.62	NR	NR	NR
	Baldazzi[157]	Octreotide 0.1 mg SC 45 min before; 6 h after ERCP	100	NR	NR	NR	NR
	Testoni[158]	Octreotide 0.2 mg SC before ERCP	60	NR	NR	NR	NR
	Testoni[29]	Octreotide 200 µg TID × 3 d before ERCP	60	NR	NR	NR	NS
Somatostatin							
	Lee[171]MC	Somatostatin 3 mg in 500 mL NS gtt 12 h starting 30min before ERCP	391	6.65	9.60	3.60	0.02
	Andriulli[158]MC	Somatostatin 750 µg IV 30 min before and continued for 6 h before ERCP		NR	NR	6.30	NS
	Arvanitidis[172]	Somatostatin 4 µg/kg gtt 12 h on identification of the papilla and before introduction of the catheter	372	NR	9.80	1.70	< 0.05
		Somatostatin 3 mg gtt 12 h on identification of the papilla and before introduction of the catheter				1.70	< 0.05
	Poon[173]	Somatostatin 250 mg IV bolus immediately after ERCP	270	NR	13.30	4.40	0.01
	Andriulli[163]MC	Somatostatin 750 µg IV 30 min before and 2 h after ERCP		NR		11.50	NS
	Poon[174]	Somatostatin 3 mg in 500 mL NS gtt for 12 h starting 30 min before ERCP	220	5.91	10.00	3.00	0.03
	Bordas[175]	Natural somatostatin 4 mg/kg IV on identification of the papilla and before introduction of the catheter	160	NR	10.00	2.50	< 0.05

PEP: Post-ERCP pancreatitis; ERCP: Endoscopic retrograde cholangiopancreatography; NS: Not significant; NR: Not reported/unable to acquire primary data from publication; MC: Multi-centered.

Table 4. Randomized controlled trails of inhibitors of pancreatic secretion evaluated for reduction or prevention of post-ERCP pancreatitis.

Agent	Author	Factor studied	n	Rate of post-ERCP pancreatitis (%)			P value
				Overall	Control	Intervention	
Injected Botulinum toxin							
	Gorelick[128]	Botulinum toxin injection after biliary sphincterotomy	26	NR	43.00	25.00	0.340
Nifedipine							
	Pratt[136]	Nifedipine 20 mg PO 3-6 h before ERCP	155	15.50	17.70	13.20	NS
	Sand[137]	Nifedipine 20 mg PO q 8 h the day of ERCP	166	3.61	4.00	4.00	NR
Nitroglycerin							
	Hao[138]	Glyceryl trinitrate 5 mg IV and 100 mg vitamin C 5 min before ERCP maneuvers	74	16.20	25.00	7.90	0.012
	Beauchant[139]MC	Nitroglycerin bolus of 0.1 mg, then 35 g/kg/min IV for 6 h after ERCP	208	12.00	15.00	10.00	0.260
	Kaffes[140]	Transdermal glyceryl trinitrate patch (15 mg) precordial area 30-40 min before ERCP	318	NR	7.40	7.70	NS
	Moretó[141]	Transdermal glyceryl trinitrate patch (15 mg) precordial area 30-40 min before ERCP	144	9.00	15.00	4.00	0.030
	Sudhindran[142]	Glyceryl trinitrate 2 mg SL 5 min before ERCP	186	13.00	18.00	8.00	< 0.050
Nafamostat mesylate							
	Choi[165]	Nafamostat mesylate 20 mg gtt 1 h before and for 24 h after ERCP	704	5.40	7.40	3.30	0.018
Pentoxifylline							
	Kapetanos[168]	Pentoxifylline 400 mg PO TID before ERCP	320	4.38	3.00	5.60	0.28
Recombinant PAF acetylhydrolase							
	Sherman[169]MC	Recombinant PAF acetylhydrolase (rPAF-AH) 1 mg/kg gtt< 1 h before ERCP	600	17.60	19.60	17.50	0.59
		Recombinant PAF acetylhydrolase (rPAF-AH) 5 mg/kg gtt< 1 h before ERCP				15.90	0.34
Semapimod							
	van Westerloo[170]	Semapimod IV 50 mg/100 mL glucose gtt 1 h before ERCP	242	11.98	14.88	9.09	0.117
Sprayed Epineprine							
	Matsushita[117]	Epinephrine (10 mL of 0.02%) sprayed on papilla before cannulation	370	1.10	2.16	0.00	0.00 0.123
Sprayed Lidocaine							
	Schwartz[176]	Lidocaine (10 mL of 1%) sprayed on the major papilla before cannulation	294	4.08	3.04	4.32	0.73

ERCP: Endoscopic retrograde cholangiopancreatography; NS: Not significant;NR: Not reported/unable to acquire primary data from publication; MC: Multi-centered.

Table 5. Randomized controlled trails of drugs that decrease Sphincter of Oddi Pressure and miscellaneous drugs evaluated for reduction or prevention of post-ERCP pancreatitis.

mg by mouth given 30–90 min before ERCP and up to 4–6 h after ERCP showed no decrease in the incidence of PEP [146]. A small clinical trial by Senol and colleagues found no significant difference in the incidence of PEP in patients given ERCP with the use of 75 mg of diclofenac by the intramuscular route plus intravenous (IV) hydration versus those given placebo and IV solutions [147]. According to the European Society of Gastrointestinal Endoscopy, no other drug prophylaxis has been proven to be effective against PEP as rectal NSAIDs [148].

Glyceryl trinitrate [141], hydrocortisone [130], and IL-10 [52] were shown to be beneficial in one RCT. However, studies with larger numbers of patients [26,54,140] found no significant effects of these treatments. Gabexate [160,161,163], octreotide [150,151], somatostatin [171,174], and ulinastatin [167] have all been reported to reduce the incidence of PEP. However, studies evaluating each of these agents using similar designs have reported no significant reduction in the incidence of PEP. These differences might be explained by differences in the selection and number of patients, clinical presentation, and timing of administration or dosage of the agents under investigation.

7. Management of PEP

Not all patients with pain and hyperamylasemia following ERCP have acute pancreatitis, and clinicians may have difficulty establishing the diagnosis. As a result, some patients with severe post-ERCP pancreatitis may not be identified in the early stages of their illness when aggressive hydration is most important. Some endoscopists may have difficulty acknowledging that post-ERCP pancreatitis has occurred, as this requires accepting that there has been a complication. A sense of guilt on the part of the clinician performing the procedure is understandable. However, delay in either the diagnosis or treatment of post-ERCP pancreatitis may lead to adverse consequences.

Post-ERCP pancreatitis should be managed as for other causes of acute pancreatitis. This is sometimes complicated by the difficulty distinguishing mild from severe disease in the early stages. The elevations in serum amylase and lipase levels do not always correlate with disease severity.

Mild and moderate PEP usually resolve quickly with conservative therapy. Although there are no specific guidelines for the treatment of PEP, a recent study found that a protocol-based management strategy was associated with less severe pancreatitis, shorter length of hospital stay, the need for fewer imaging studies, and less use of antibiotics [109,177].

Practice guidelines for acute pancreatitis treatment are available and may be applicable to PEP as well [47]. In patients with persistent or severe PEP, two important markers of severity are multisystem organ failure and pancreatic necrosis, both of which require aggressive management [18]. Early identification of organ failure, pancreatic necrosis, perforation (especially in the setting of endoscopic sphincterotomy), biliary damage/leak and pancreatic fluid collections are important clinical branch points that may require more intensive intervention. Checking the levels of serum transaminases, amylase, and lipase is not routinely recommended after ERCP, but if assessed, postprocedure elevations occur often. These elevations are likely to be secondary to intermittent biliary, pancreatic, or papillary obstruction. In a recent study, 46% of patients had elevated liver test results after ERCP, but only 5.4% had PEP [110]. Asymptomatic elevation of liver markers is not an indication for a change in management and a repeat ERCP should be performed only with a clear indication. Although the use of enteral feeding during treatment of acute pancreatitis is

controversial, patients who are unlikely to resume oral nutrition within 5 days require nutritional support, which can be provided via total parenteral nutrition or enteral routes [177]. There appear to be some advantages to enteral feeding. A recent study found that initiating oral nutrition after mild acute pancreatitis with a low-fat soft diet appeared to be safe but did not shorten the length of hospitalization [111].

8. Conclusion

Acute pancreatitis is a well-recognized and frequent complication that can occur in 1%–15% of patients undergoing ERCP. Clinical research to prevent PEP using depurate endoscopic techniques and pharmacological prophylaxis is intense and so far indicates that the use of NSAIDs and pancreatic stenting, coupled with appropriate selection of eligible patients and performed by an experienced endoscopist are the most effective preventive measures to reduce the incidence and severity this complication.

9. References

[1] Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001;54(4):425-34.

[2] Rabenstein T, Hahn EG. Post-ERCP pancreatitis: New momentum. Endoscopy 2002; 34: 325-9.

[3] Frank CD, Adler DG. Post-ERCP Pancreatitis and its prevention. Nat Clin Pract Gastroenterol Hepatol 2006;3:680-8.

[4] LaFerla G, Gordon S , Archibald M, Murray WR. Hyperamylasaemia and acute pancreatitis following endoscopic retrograde cholangiopancreatography. Pancreas. 1986;1(2):160-63.

[5] Badalov N, Tenner S, Baillie J. The Prevention, recognition and treatment of post-ERCP pancreatitis. JOP. 2009;10(2):88-97.

[6] Vandervoort J, Soetikno RM, Tham TC, Wong RC, Ferrari AP Jr, Montes H, et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc. 2002;56(5):652-6.

[7] García-Cano Lizcano J, González Martín JA, Morillas Ariño J, Pérez Sola A. Complications of endoscopic retrograde cholangiopancreatography. A study in a small ERCP unit. Rev Esp Enferm Dig. 2004;96(3):163-73.

[8] Cheng CL, Sherman S, Watkins JL, Barnett J, Freeman M, Geenen J, et al. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol. 2006;101(1):139-47.

[9] Williams EJ, Taylor S, Fairclough P, Hamlyn A, Logan RF, Martin D, et al. Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study. Endoscopy. 2007;39(9):793-801.

[10] Freeman ML, Guda NM. Prevent ion of post - ERCP pancreatitis: a comprehensive review. Gastrointest Endosc. 2004;59(7):845-64

[11] Ito K, Fujita N, Noda Y, Kobayashi G, Horaguchi J, Takasawa O, Obana T.Relationship between post-ERCP pancreatitis and the change of serum amylase level after the procedure. World J Gastroenterol 2007; 13:3855-60.

[12] Bilbao MK, Dotter CT, Lee TG, Katon RM. Complications of endoscopic retrograde cholangiopancreatography (ERCP). A study of 10,000 cases. Gastroenterology. 1976;70(3):314-20.

[13] Skude G, Wehlin L, Maruyama T, Ariyama J. Hyperamylasaemia after duodenoscopy and retrograde cholangiopancreatography. Gut. 1976;17(2):127-32.

[14] Silviera ML, Seamon MJ, Porshinsky B, Prosciak MP, Doraiswamy VA, Wang CF, et al. Complications related to endoscopic retrograde cholangiopancreatography: a comprehensive clinical review. J Gastrointestin Liver Dis. 2009;18(1):73-82.

[15] Wang P, Li ZS, Liu F, Ren X, Lu NH, Fan ZN, et al. Risk factors for ERCP-related complications: a prospective multicenter study. Am J Gastroenterol. 2009;104(1):31-40.

[16] Cohen S, Bacon BR, Berlin JA, Fleischer D, Hecht GA, Loehrer PJ Sr, et al. National Institutes of Health State-of-the-Science Conference Statement: ERCP for diagnosis and therapy, January 14-16, 2002. Gastrointest Endosc. 2002;56(6):803-9.

[17] Brugge WR, Van Dam J. Pancreatic and biliary endoscopy. N Engl J Med. 1999;341(24):1808-16.

[18] Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 1991;37(3):383-93.

[19] Testoni PA, Bagnolo F, Caporuscio S, Lella F. Serum amylase measured four hours after endoscopic sphincterotomy is a reliable predictor of postprocedure pancreatitis. Am J Gastroenterol. 1999;94(5):1235-41.

[20] Testoni PA, Cicardi M, Bergamaschini L, Guzzoni S, Cugno M, Buizza M, et al. Infusion of C1-inhibitor plasma concentrate prevents hyperamylasemia induced by endoscopic sphincterotomy. Gastrointest Endosc. 1995;42(4):301-5.

[21] Testoni PA, Bagnolo F. Pain at 24 hours associated with amylase levels greater than 5 times the upper normal limit as the most reliable indicator of post-ERCP pancreatitis. Gastrointest Endosc. 2001;53(1):33-9.

[22] Testoni PA, Bagnolo F, Natale C, Primignani M. Incidence of post-endoscopic retrograde-cholangiopancreatography/sphincterotomy pancreatitis depends upon definition criteria. Dig Liver Dis. 2000;32(5):412-8.

[23] Weiner GR, Geenen JE, Hogan WJ, Catalano MF. Use of corticosteroids in the prevention of post-ERCP pancreatitis. Gastrointest Endosc. 1995;42(6):579-83.

[24] Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med. 1996;335(13):909-18.

[25] Johnson GK, Geenen JE, Johanson JF, Sherman S, Hogan WJ, Cass O. Evaluation of post-ERCP pancreatitis: potential causes noted during controlled study of differing contrast media. Midwest Pancreaticobiliary Study Group. Gastrointest Endosc. 1997;46(3):217-22.

[26] De Palma GD, Catanzano C. Use of corticosteriods in the prevention of post-ERCP pancreatitis: results of a controlled prospective study. Am J Gastroenterol. 1999;94(4):982-5.

[27] Sherman S, Ruffolo TA, Hawes RH, Lehman GA. Complications of endoscopic sphincterotomy. A prospective series with emphasis on the increased risk

associated with sphincter of Oddi dysfunction and nondilated bile ducts. Gastroenterology. 1991;101(4):1068-75.

[28] Sherman S, Hawes RH, Rathgaber SW, Uzer MF, Smith MT, Khusro QE, et al. Post-ERCP pancreatitis: randomized, prospective study comparing a low- and high-osmolality contrast agent. Gastrointest Endosc. 1994;40(4):422-427.

[29] Testoni PA, Lella F, Bagnolo F, Caporuscio S, Cattani L, Colombo E, et al. Long-term prophylactic administration of octreotide reduces the rise in serum amylase after endoscopic procedures on Vater's papilla. Pancreas. 1996;13(1):61-5.

[30] Masci E, Toti G, Mariani A, Curioni S, Lomazzi A, Dinelli M, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study Am J Gastroenterol. 2001;96(2):417-23.

[31] Abid GH, Siriwardana HP, Holt A, Ammori BJ. Mild ERCP induced and non-ERCP-related acute pancreatitis: two distinct clinical entities? J Gastroenterol. 2007;42(2):146-51.

[32] Chen CC, Wang SS, Lu RH, Lu CC, Chang FY, Lee SD. Early changes of serum proinflammatory and anti-inflammatory cytokines after endoscopic retrograde cholangiopancreatography. Pancreas. 2003;26(4):375-80.

[33] Bradley EL 3rd. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg. 1993;128(5):586-90.

[34] Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE. APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med. 1981;9(8):591-7.

[35] Ranson JH, Rifkind KM, Roses DF, Fink SD, Eng K, Spencer FC. Prognostic signs and the role of operative management in acute pancreatitis. Surg Gynecol Obstet. 1974;139(1):69-81.

[36] Bhatia V, Garg PK, Tandon RK, Madan K. Endoscopic retrograde cholangiopancreatography-induced acute pancreatitis often has a benign outcome. J Clin Gastroenterol. 2006;40(8):726-31.

[37] Barkay O, Niv E, Santo E, Bruck R, Hallak A, Konikoff FM. Low-dose heparin for the prevention of post-ERCP pancreatitis: a randomized placebo-controlled trial. Surg Endosc. 2008;22(9):1971-76.

[38] Conwell DL, O'Connor JB, Ferguson DR, Vargo JJ, Barnes DS, et al. Pretreatment with methylprednisolone to prevent ERCP-induced pancreatitis: a randomized, multicenter, placebo-controlled clinical trial. Am J Gastroenterol. 1998;93(1):61-5.

[39] Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology. 2003;124(7):1786-91.

[40] Tulassay Z, Döbrönte Z, Prónai L, Zágoni T, Juhász L. Octreotide in the prevention of pancreatic injury associated with endoscopic cholangiopancreatography. Aliment Pharmacol Ther. 1998;12(11):1109-12.

[41] Sherman S, Lehman GA. ERCP and endoscopic sphincterotomy-induced pancreatitis. Pancreas. 1991;6(3):350-67.

[42] Pezzilli R, Romboli E, Campana D, Corinaldesi R. Mechanisms involved in the onset of post-ERCP pancreatitis. JOP. 2002;3(6):162-8.

[43] Messmann H, Vogt W, Holstege A, Lock G, Heinisch A, von Fürstenberg A, et al. Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis. Gut. 1997;40(1):80-5.

[44] Oezcueruemez-Porsch M, Kunz D, Hardt PD, Fadgyas T, Kress O, Schulz HU, et al. Diagnostic relevance of interleukin pattern, acute-phase proteins, and procalcitonin in early phase of post-ERCP pancreatitis. Dig Dis Sci. 1998;43(8):1763-69.

[45] Cooper ST, Slivka A. Incidence, risk factors, and prevention of post-ERCP pancreatitis. Gastroenterol Clin North Am. 2007;36(2):259-76.

[46] Mohseni Salehi Monfared SS, Vahidi H, Abdolghaffari AH, Nikfar S, Abdollahi M. Antioxidant therapy in the management of acute, chronic and post-ERCP pancreatitis: a systematic review. World J Gastroenterol 2009;15:4481-90.

[47] Banks PA, Freeman ML; Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101(10):2379-400.

[48] Kilciler G, Musabak U, Bagci S, Yesilova Z, Tuzun A, Uygun A, et al. Do the changes in the serum levels of IL-2, IL-4, TNFalpha, and IL-6 reflect the inflammatory activity in the patients with post-ERCP pancreatitis? Clin Dev Immunol. 2008;2008:481560.

[49] Sultan S, Baillie J. What are the predictors of post-ERCP pancreatitis, and how useful are they? JOP. 2002;3(6):188-94.

[50] Demols A, Deviere J. New frontiers in the pharmacology prevention of post-ERCP pancreatitis: the cytokines. JOP. 2003;4(1):49-57.

[51] Pande H, Thuluvath P. Pharmacological prevention of postendoscopic retrograde cholangiopancreatography pancreatitis. Drugs. 2003;63(17):1799-812.

[52] Devière J, Le Moine O, Van Laethem JL, Eisendrath P, Ghilain A, Severs N, et al. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology. 2001;120(2):498-505.

[53] Dumot JA, Conwell DL, Zuccaro G Jr, Vargo JJ, Shay SS, Easley KA, et al. A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol. 2001;96(7):2098-102.

[54] Sherman S, Cheng CL, Costamagna G, Binmoeller KF, Puespoek A, Aithal GP, et al. Efficacy of recombinant human interleukin-10 in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk. Pancreas. 2009;38(3):267-74.

[55] Deschamps JP, Allemand H, Janin Magnificat R, Camelot G, Gillet M, Carayon P. Acute pancreatitis following gastrointestinal endoscopy without ampullary cannulation. Endoscopy. 1982;14(3):105-6.

[56] Williams EJ, Taylor S, Fairclough P, Hamlyn A, Logan RF, Martin D, et al. Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study. Endoscopy. 2007;39(9):793-801.

[57] Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc. 2001;54(4):425-34.

[58] Andriulli A, Solmi L, Loperfido S, Leo P, Festa V, Belmonte A, et al. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol. 2004;2(8):713-8.

[59] Cheon YK, Cho KB, Watkins JL, McHenry L, Fogel EL, Sherman S, et al. Frequency and severity of post-ERCP pancreatitis correlated with extent of pancreatic ductal opacification. Gastrointest Endosc. 2007;65(3):385-93.

[60] Jowell PS, Baillie J, Branch MS, Affronti J, Browning CL, Bute BP. Quantitative assessment of procedural competence. A prospective study of training in endoscopic retrograde cholangiopancreatography. Ann Intern Med. 1996;125(12):983-9.

[61] Baron Baron TH, Petersen BT, Mergener K, Chak A, Cohen J, Deal SE, et al. Quality indicators for endoscopic retrograde cholangiopancreatography. Am J Gastroenterol. 2006;101(4):892-7.

[62] Kapral C, Duller C, Wewalka F, Kerstan E, Vogel W, Schreiber F. Case volume and outcome of endoscopic retrograde cholangiopancreatography: results of a nationwide Austrian benchmarking project. Endoscopy. 2008;40(8):625-30.

[63] Cotton PB, Garrow DA, Gallagher J, Romagnuolo J. Risk factors for complications after ERCP: a multivariate analysisof 11,497 procedures over 12 years. Gastrointest Endosc. 2009;70(1):80-8.

[64] Williams EJ, Taylor S, Fairclough P, Hamlyn A, Logan RF, Martin D, et al. Are we meeting the standards set for endoscopy? Results of a large-scale prospective survey of endoscopic retrograde cholangio-pancreatograph practice. Gut. 2007;56(6):821-9.

[65] Vitte RL, Morfoisse JJ; Investigator Group of Association Nationale des Gastroentérologues des Hôpitaux Généraux. Evaluation of endoscopic retrograde cholangiopancreatography procedures performed in general hospitals in France. Gastroenterol Clin Biol. 2007;31(8-9 Pt 1):740-9.

[66] Freeman ML, Guda NM. ERCP cannulation: a review of reported techniques. Gastrointest Endosc. 2005;61(1):112-25.

[67] Cortas GA, Mehta SN, Abraham NS, Barkun AN. Selective cannulation of the common bile duct: a prospective randomized trial comparing standard catheters with sphincterotomes. Gastrointest Endosc. 1999;50(6):775-9.

[68] Lella F, Bagnolo F, Colombo E, Bonassi U. A simple way of avoiding post-ERCP pancreatitis. Gastrointest Endosc. 2004;59(7):830-834.

[69] Artifon EL, Sakai P, Cunha JE, Halwan B, Ishioka S, Kumar A. Guidewire cannulation reduces risk of post-ERCP pancreatitis and facilitates bile duct cannulation. Am J Gastroenterol. 2007;102(10):2147-53.

[70] Ito K, Fujita N, Noda Y, Kobayashi G, Obana T, Horaguchi J, et al. Pancreatic guidewire placement for achieving selective biliary cannulation during endoscopic retrograde cholangio-pancreatography. World J Gastroenterol. 2008;14(36):5595-6000.

[71] Lee TH, Park do H, Park JY, Kim EO, Lee YS, Park JH, et al. Can wire-guided cannulation prevent post-ERCP pancreatitis? A prospective randomized trial. Gastrointest Endosc. 2009;69(3 Pt 1):444-9.

[72] Bailey AA, Bourke MJ, Williams SJ, Walsh PR, Murray MA, Lee EY, et al. A prospective randomized trial of cannulation technique in ERCP: effects on technical success and post-ERCP pancreatitis. Endoscopy. 2008;40(4):296-301.

[73] Barkin JS, Casal GL, Reiner DK, Goldberg RI, Phillips RS, Kaplan S. A comparative study of contrast agents for endoscopic retrograde pancreatography. Am J Gastroenterol. 1991;86(10):1437-41.

[74] Johnson GK, Geenen JE, Bedford RA, Johanson J, Cass O, Sherman S, et al. A comparison of nonionic versus ionic contrast media: results of a prospective, multicenter study. Midwest Pancreaticobiliary Study Group. Gastrointest Endosc. 1995;42(4):312-6.

[75] George S, Kulkarni AA, Stevens G, Forsmark CE, Draganov P. Role of osmolality of contrast media in the development of post-ERCP pancreatitis: a metanalysis. Dig Dis Sci. 2004;49(3):503-8.

[76] Tarnasky PR, Palesch YY, Cunningham JT, Mauldin PD, Cotton PB, Hawes RH. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology. 1998;115(6):1518-24.

[77] Harewood GC, Pochron NL, Gostout CJ. Prospective, randomized, controlled trial of prophylactic pancreatic stent placement for endoscopic snare excision of the duodenal ampulla. Gastrointest Endosc. 2005;62(3):367-370.

[78] Sofuni A, Maguchi H, Itoi T, Katanuma A, Hisai H, Niido T, et al. Prophylaxis of postendoscopic retrograde cholangiopancreatography pancreatitis by an endoscopic pancreatic spontaneous dislodgement stent. Clin Gastroenterol Hepatol. 2007;5(11):1339-46.

[79] Freeman ML. Pancreatic stents for prevention of postendoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol. 2007;5(11):1354-65.

[80] Tarnasky PR. Mechanical prevention of post-ERCP pancreatitis by pancreatic stents: results, techniques, and indications. JOP. 2003;4(1):58-67.

[81] Fazel A, Quadri A, Catalano MF, Meyerson SM, Geenen JE. Does a pancreatic duct stent prevent post-ERCP pancreatitis?. A prospective randomized study. Gastrointest Endosc. 2003;57(3):291-4.

[82] Simmons DT, Petersen BT, Gostout CJ, Levy MJ, Topazian MD, Baron TH. Risk of pancreatitis following endoscopically placed large-bore plastic biliary stents with and without biliary sphincterotomy for management of postoperative bile leaks. Surg Endosc. 2008;22(6):1459-63.

[83] Smithline A, Silverman W, Rogers D, Nisi R, Wiersema M, Jamidar P, et al. Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients. Gastrointest Endosc 1993; 39: 652-7

[84] Tsuchiya T, Itoi T, Sofuni A, Itokawa F, Kurihara T, Ishii K et al. Temporary pancreatic stent to prevent post endoscopic retrograde cholangiopancreatography pancreatitis: a preliminary, single-center, randomized controlled trial. J Hepatobiliary Pancreat Surg. 2007;14(3):302-307.

[85] Fogel EL, Eversman D, Jamidar P, Sherman S, Lehman GA. Sphincter of Oddi dysfunction: pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone. Endoscopy. 2002;34(4):280-5.

[86] Andriulli A, Forlano R, Napolitano G, Conoscitore P, Caruso N, Pilotto A, et al. Pancreatic duct stents in the prophylaxis of pancreatic damage after endoscopic retrograde cholangiopancreatography: a systemic analysis of benefits and associated risks. Digestion. 2007;75(2-3):156-163.

[87] Masci E, Mariani A, Curioni S, Testoni PA. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis. Endoscopy. 2003;35(10):830-4.

[88] Singh P, Das A, Isenberg G, Wong RC, Sivak MV Jr, Agrawal D, et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled studies. Gastrointest Endosc. 2004;60(4):544-50.

[89] Mazaki T, Masuda H, Takayama T. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: a systematic review and meta-analysis. Endoscopy. 2010;42(10):842-53.

[90] Choudhary A, Bechtold ML, Arif, M, Szary NM, Puli SR, Othman MO, Pais WP, Antillon MR, et al. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. Gastrointest Endosc. 2011;73(2):275-82.

[91] Deviere J. Pancreatic Stents. Gastrointest Endosc Clin N Am. 2011;21(3):499-510.

[92] Arnold JC, Benz C, Martin WR, Adamek HE, Riemann JF. Endoscopic papillary balloon dilation vs. sphincterotomy for removal of common bile duct stones: a prospective randomized pilot study. Endoscopy. 2001;33(7):563-7.

[93] Disario JA. Endoscopic balloon dilation for extraction of bile duct stones: the devil is in the details. Gastrointest Endosc. 2003;57(2):282-5.

[94] Fujita N, Maguchi H, Komatsu Y, Yasuda I, Hasebe O, Igarashi Y, et al. Endoscopic sphincterotomy and endoscopic papillary balloon dilatation for bile duct stones: A prospective randomized controlled multicenter trial. Gastrointest Endosc 2003; 57: 151-5.

[95] Vlavianos P, Chopra K, Mandalia S, Anderson M, Thompson J, Westaby D. Endoscopic balloon dilatation versus endoscopic sphincterotomy for the removal of bile duct stones: a prospective randomised trial. Gut. 2003;52(8):1165-9.

[96] Song SY, Lee KS, Na KJ, Ahn BH. Tension pneumothorax after endoscopic retrograde pancreatocholangiogram. J Korean Med Sci. 2009;24(1):173-5.

[97] García-Cano J. Fatal pancreatitis after endoscopic balloon dilation for extraction of common bile duct stones in an 80-year-old woman. Endoscopy. 2007;39 Suppl 1:E132.

[98] Mao Z, Zhu Q, Wu W, Wang M, Li J, Lu A, et al. Duodenal perforations after endoscopic retrograde cholangiopancreatography: experience and management. J Laparoendosc Adv Surg Tech A. 2008;18(5):691-5.

[99] Margantinis G, Sakorafas GH, Kostopoulos P, Kontou S, Tsiakos S, Arvanitidis D. Post-ERCP/endoscopic sphincterotomy duodenal perforation is not always a surgical emergency. Dig Liver Dis. 2006;38(6):434-6.

[100] Park DH, Kim MH, Lee SK, Lee SS, Choi JS, Song MH, et al. Endoscopic sphincterotomy vs. endoscopic papillary balloon dilation for choledocholithiasis in patients with liver cirrhosis and coagulopathy. Gastrointest Endosc. 2004;60(2):180-5.

[101] Cotton PB. ERCP is most dangerous for people who need it least. Gastrointest Endosc. 2001;54(4):535-6.

[102] Woods KE, Willingham FF. Endoscopic retrograde cholangiography associated pancreatitis: A 15-year review. World J Gastrointest Endosc 2010;2: 165-78.

[103] Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De Berardinis F, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc. 1998;48(1):1-10.

[104] Christoforidis E, Goulimaris I, Kanellos I, Tsalis K, Demetriades C, Betsis D. Post-ERCP pancreatitis and hyperamylasemia: patient-related and operative risk factors. Endoscopy. 2002;34(4):286-92.

[105] Tarnasky P, Cunningham J, Cotton P, Hoffman B, Palesch Y, Freeman J, et al. Pancreatic sphincter hypertension increases the risk of post-ERCP pancreatitis. Endoscopy. 1997;29(4):252-7.

[106] Deenadayalu VP, Blaut U, Watkins JL, Barnett J, Freeman M, Geenen J, et al. Does obesity confer an increased risk and/or more severe course of post-ERCP pancreatitis?: a retrospective, multicenter study. J Clin Gastroenterol. 2008;42(10):1103-9.

[107] Lukens FJ, Howell DA, Upender S, Sheth SG, Jafri SM. ERCP in the very elderly: outcomes among patients older than eighty. Dig Dis Sci. 2010;55(3):847-51.

[108] Debenedet AT, Raghunathan TE, Wing JJ, Wamsteker EJ, DiMagno MJ. Alcohol use and cigarette smoking as risk factors for post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol. 2009;7(3):353-8e4.

[109] Reddy N, Wilcox CM, Tamhane A, Eloubeidi MA, Varadarajulu S. Protocol-based medical management of post-ERCP pancreatitis. J Gastroenterol Hepatol. 2008;23(3):385-92.

[110] Silverman WB, Thompson RA. Management of asymptomatically/minimally symptomatic post-ERCP serum liver test elevations: first do no harm. Dig Dis Sci. 2002;47(7):1498-501.

[111] Jacobson BC, Vander Vliet MB, Hughes MD, Maurer R, McManus K, Banks PA. A prospective, randomized trial of clear liquids versus low-fat solid diet as the initial meal in mild acute pancreatitis. Clin Gastroenterol Hepatol. 2007;5(8):946-51.

[112] Dundee PE, Chin-Lenn L, Syme DB, Thomas PR. Outcomes of ERCP: prospective series from a rural centre. ANZ J Surg. 2007;77(11):1013-7.

[113] Barthet M, Lesavre N, Desjeux A, Gasmi M, Berthezene P, Berdah S, et al. Complications of endoscopic sphincterotomy: results from a single tertiary referral center. Endoscopy. 2002;34(12):991-7.

[114] Andriulli A, Loperfido S, Napolitano G, Niro G, Valvano MR, Spirito F, et al. Incidence rates of post- ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol. 2007;102(8):1781-8.

[115] Disario JA, Freeman ML, Bjorkman DJ, Macmathuna P, Petersen BT, Jaffe PE, et al. Endoscopic balloon dilation compared with sphincterotomy for extraction of bile duct stones. Gastroenterology. 2004;127(5):1291-9.

[116] Bergman JJ, Rauws EA, Fockens P, van Berkel AM, Bossuyt PM, Tijssen JG, et al. Randomised trial of endoscopic balloon dilation versus endoscopic sphincterotomy for removal of bileduct stones. Lancet. 1997;349(9059):1124-9.

[117] Matsushita M, Takakuwa H, Shimeno N, Uchida K, Nishio A, Okazaki K. Epinephrine sprayed on the papilla for prevention of post-ERCP pancreatitis. J Gastroenterol 2009; 44: 71-5

[118] Dumot JA, Conwell DL, O'Connor JB, Ferguson DR, Vargo JJ, Barnes DS, et al. Pretreatment with methylprednisolone to prevent ERCP-induced pancreatitis: a randomized, multicenter, placebo-controlled clinical trial. Am J Gastroenterol 1998; 93: 61-5.

[119] Martinez-Torres H, Rodriguez-Lomeli X, Davalos-Cobian C, Garcia-Correa J, Maldonado-Martinez JM, Medrano-Muñoz F, et al. Oral allopurinol to prevent hyperamylasemia and acute pancreatitis after endoscopic retrograde cholangiopancreatography. World J Gastroenterol. 2009;15(13):1600-6.

[120] Katsinelos P, Kountouras J, Chatzis J, Christodoulou K, Paroutoglou G, Mimidis K, et al. Highdose allopurinol for prevention of post-ERCP pancreatitis: a prospective randomized double-blind controlled trial. Gastrointest Endosc. 2005;61(3):407-15.

[121] Romagnuolo J, Hilsden R, Sandha GS, Cole M, Bass S, May G, et al. Allopurinol to prevent pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized placebo-controlled trial. Clin Gastroenterol Hepatol. 2008;6(4):465-71.

[122] Mosler P, Sherman S, Marks J, Watkins JL, Geenen JE, Jamidar P, et al. Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis. Gastrointest Endosc. 2005;62(2):245-50.

[123] Budzyńska A, Marek T, Nowak A, Kaczor R, Nowakowska-Dulawa E. A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. Endoscopy. 2001;33(9):766-72.

[124] Dai H-F, Wang X-W, Zhao K. Role of nonsteroidal anti-inflammatory drugs in the prevention of post-ERCP pancreatitis: a meta-analysis. Hepatobiliary Pancreat Dis Int 2009; 8: 11 – 6.

[125] Elmunzer B, Waljee A, Elta G, Taylor JR, Fehmi SM, Higgins PD. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut 2008; 57: 1262-7.

[126] Zheng M-H, Xia H, Chen Y-P. Rectal administration of NSAIDs in the prevention of post-ERCP pancreatitis: a complementary meta-analysis. Gut 2008; 57: 1632-3.

[127] Lavy A, Karban A, Suissa A, Yassin K, Hermesh I, Ben-Amotz A. Natural beta-carotene for the prevention of post-ERCP pancreatitis. Pancreas 2004; 29(2): e45-e50.

[128] Gorelick A, Barnett J, Chey W, Anderson M, Elta G. Botulinum toxin injection after biliary sphincterotomy. Endoscopy 2004; 36(2): 170-3.

[129] Räty S, Sand J, Pulkkinen M, Matikainen M, Nordback I. Post-ERCP pancreatitis: reduction by routine antibiotics. J Gastrointest Surg 2001; 5(4): 339-45.

[130] Kwanngern K, Tiyapattanaputi P, Wanitpukdeedecha M, Navicharern P. Can a single dose corticosteroid reduce the incidence of post-ERCP pancreatitis? A randomized, prospective control study. J Med Assoc Thai 2005; 88 Suppl 4:S42-5.

[131] Manolakopoulos S, Avgerinos A, Vlachogiannakos J, Armonis A, Viazis N, Papadimitriou N, et al. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. Gastrointest Endosc 2002; 55(4):470-5.

[132] Sherman S, Blaut U, Watkins JL, Barnett J, Freeman M, Geenen J, et al. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study. Gastrointest Endosc 2003; 58(1):23-9.

[133] Rabenstein T, Fischer B, Wiessner V, Schmidt H, Radespiel-Tröger M, Hochberger J, et al. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc. 2004;59(6):606-13.

[134] Milewski J, Rydzewska G, Degowska M, Kierzkiewicz M, Rydzewski A. N-acetylcysteine does not prevent postendoscopic retrograde cholangiopancreatography hyperamylasemia and acute pancreatitis. World J Gastroenterol. 2006;12(23):3751-5.

[135] Katsinelos P, Kountouras J, Paroutoglou G, Beltsis A, Mimidis K, Zavos C. Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis. Gastrointest Endosc. 2005;62(1):105-11.

[136] Prat F, Amaris J, Ducot B, Bocquentin M, Fritsch J, Choury AD, et al. Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc. 2002;56(2):202-8.

[137] Sand J, Nordback I. Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography Digestion. 1993;54(2):105-11.

[138] Hao JY, Wu DF, Wang YZ, Gao YX, Lang HP, Zhou WZ. Prophylactic effect of glyceryl trinitrate on post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized placebo-controlled trial. World J Gastroenterol. 2009;15(3):366-8.

[139] Beauchant M, Ingrand P, Favriel JM, Dupuychaffray JP, Capony P, Moindrot H, et al.. Intravenous nitroglycerin for prevention of pancreatitis after therapeutic endoscopic retrograde cholangiography: a randomized, double-blind, placebo-controlled multicenter trial. Endoscopy. 2008;40(8):631-6.

[140] Kaffes AJ, Bourke MJ, Ding S, Alrubaie A, Kwan V, Williams SJ. A prospective, randomized, placebo-controlled trial of transdermal glyceryl trinitrate in ERCP: effects on technical success and post-ERCP pancreatitis. Gastrointest Endosc. 2006;64(3):351-7

[141] Moretó M, Zaballa M, Casado I, Merino O, Rueda M, Ramírez K, et al. Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: A randomized double-blind trial. Gastrointest Endosc. 2003;57(1):1-7.

[142] Sudhindran S, Bromwich E, Edwards PR. Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis. Br J Surg. 2001;88(9):1178-82.

[143] Khoshbaten M, Khorram H, Madad L, Ehsani Ardakani MJ, Farzin H, Zali MR. Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis. J Gastroenterol Hepatol. 2008;23(7 Pt 2):e11-6.

[144] Montaño-Loza A, Rodriguez-Lomeli X, Garcia-Correa J, Fuentes Orozco C, González Ojeda A, Medrano Munoz F, et al. Effect of rectal administration of indomethacin on amylase serum levels after endoscopic retrograde cholangiopancreatography, and its impact on the development of secondary pancreatitis episodes. Rev Esp Enferm Dig 2007;99(6):330–6.

[145] Sotoudehmanesh R, Khatibian M, Kolahdoozan S, Ainechi S, Malboosbaf R, Nouraie M. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol. 2007;102(5):978-83.

[146] Cheon YK, Cho KB, Watkins JL, McHenry L, Fogel EL, Sherman S, et al. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk

            patients: a randomized double blind prospective trial. Gastrointest Endosc.
            2007;66(6):1126 - 32.

[147] Senol A, Saritas U, Demirkan H. Efficacy of intramuscular diclofenaco and fluid
            replacement in prevention of post-ERCP pancreatitis. World J Gastroenterol
            2009;15(32):3999-4004.

[148] Dumonceau JM , Andriulli A, Deviere J, Mariani A, Rigaux J , Baron TH, et al.
            European Society of Gastrointestinal Endoscopy (ESGE) Guideline: Prophylaxis of
            post-ERCP pancreatitis. Prophylaxis. Endoscopy 2010; 42: 503 – 15

[149] Kisli E, Baser M, Aydin M, Guler O. The role of octreotide versus placebo in the
            prevention of post-ERCP pancreatitis. Hepatogastroenterology. 2007;54(73):250-3.

[150] Li ZS, Pan X, Zhang WJ, Gong B, Zhi FC, Guo XG, et al. Effect of octreotide
            administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia:
            A multicenter, placebo-controlled, randomized clinical trial. Am J Gastroenterol.
            2007;102(1):46-51.

[151] Thomopoulos KC, Pagoni NA, Vagenas KA, Margaritis VG, Theocharis GI,
            Nikolopoulou VN. Twenty-four hour prophylaxis with increased dosage of
            octreotide reduces the incidence of post-ERCP pancreatitis. Gastrointest Endosc.
            2006;64(5):726-31.

[152] Testoni PA, Bagnolo F, Andriulli A, Bernasconi G, Crotta S, Lella F, et al. Octreotide 24-
            h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a
            multicenter, randomized, controlled trial. Aliment Pharmacol Ther. 2001;15(7):965-
            72.

[153] Hardt PD, Kress O, Fadgyas T, Doppl W, Schnell-Kretschmer H, Wüsten O, et al.
            Octreotide in the prevention of pancreatic damage induced by endoscopic
            sphincterotomy. Eur J Med Res. 2000;5(4):165-70.

[154] Duvnjak M, Supanc V, Simicević VN, Hrabar D, Troskot B, Smircić-Duvnjak L, et al.
            Use of octreotideacetate in preventing pancreatitis-like changes following
            therapeutic endoscopic retrograde cholangiopancreatography. Acta Med Croatica.
            1999;53(3):115-8.

[155] Arvanitidis D, Hatzipanayiotis J, Koutsounopoulos G, Frangou E. The effect of
            octreotide on the prevention of acute pancreatitis and hyperamylasemia after
            diagnostic and therapeutic ERCP. Hepatogastroenterology. 1998 ;45(19):248-52.

[156] Arcidiacono R, Gambitta P, Rossi A, Grosso C, Bini M, Zanasi G. The use of a long-
            acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after
            endoscopic sphincterotomy. Endoscopy. 1994;26(9):715-8.

[157] Baldazzi G, Conti C, Spotti EG, Arisi GP, Scevola M, Gobetti F, et al. Prevention of
            post-ERCP acute pancreatitis with octreotide. G Chir. 1994;15(8-9):359-62.

[158] Testoni PA, Lella F, Bagnolo F, Buizza M, Colombo E. Controlled trial of different
            dosages of octreotide in the prevention of hyperamylasemia induced by endoscopic
            papillosphincterotomy. Ital J Gastroenterol. 1994;26(9):431-6.

[159] Ueki T, Otani K, Kawamoto K, Shimizu A, Fujimura N, Sakaguchi S, et al. Comparison
            between ulinastatin and gabexate mesylate for the prevention of post-endoscopic
            retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial.
            J Gastroenterol. 2007;42(2):161-7.

[160] Manes G, Ardizzone S, Lombardi G, Uomo G, Pieramico O, Porro GB. Efficacy of
            postprocedure administration of gabexate mesylate in the prevention of post-ERCP

pancreatitis: a randomized, controlled, multicenter study Gastrointest Endosc. 2007;65(7):982-7.

[161] Xiong GS, Wu SM, Zhang XW, Ge ZZ. Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis. Braz J Med Biol Res. 2006;39(1):85-90

[162] Fujishiro H, Adachi K, Imaoka T, Hashimoto T, Kohge N, Moriyama N, et al. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study. J Gastroenterol Hepatol. 2006;21(6):1065-9.

[163] Andriulli A, Clemente R, Solmi L, Terruzzi V, Suriani R, Sigillito A, et al. Gabexate or somatostatin administration before ERCP in patients athigh risk for post-ERCP pancreatitis: a multicenter, placebo controlled, randomized clinical trial. Gastrointest Endosc. 2002;56(4):488-95.

[164] Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group. N Engl J Med. 1996;335(13):919-23.

[165] Choi CW, Kang DH, Kim GH, Eum JS, Lee SM, Song GA, et al. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis. Gastrointest Endosc. 2009 Apr;69(4):e11-8.

[166] Yoo JW, Ryu JK, Lee SH, Woo SM, Park JK, Yoon WJ, et al. Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebo-controlled trial. Pancreas. 2008;37(4):366-70.

[167] Tsujino T, Komatsu Y, Isayama H, Hirano K, Sasahira N, Yamamoto N, et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol. 2005;3(4):376-83.

[168] Kapetanos D, Kokozidis G, Christodoulou D, Mistakidis K, Sigounas D, Dimakopoulos K, et al.. A randomized controlled trial of pentoxifylline for the prevention of post-ERCP pancreatitis. Gastrointest Endosc. 2007;66(3):513-8.

[169] Sherman S, Alazmi WM, Lehman GA, Geenen JE, Chuttani R, Kozarek RA, et al. Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of post-ERCP acute pancreatitis. Gastrointest Endosc. 2009;69(3 Pt 1):462-72.

[170] van Westerloo DJ, Rauws EA, Hommes D, de Vos AF, van der Poll T, Powers BL, et al. Pre-ERCP infusion of semapimod, a mitogen-activated protein kinases inhibitor, lowers post-ERCP hyperamylasemia but not pancreatitis incidence. Gastrointest Endosc. 2008;68(2):246-54.

[171] Lee KT, Lee DH, Yoo BM. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial. Pancreas. 2008;37(4):445-8.

[172] Arvanitidis D, Anagnostopoulos GK, Giannopoulos D, Pantes A, Agaritsi R, Margantinis G, et al. Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial. J Gastroenterol Hepatol. 2004;19(3):278-82.

[173] Poon RT, Yeung C, Liu CL, Lam CM, Yuen WK, Lo CM, et al. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of

pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomized controlled trial. Gut. 2003;52(12):1768-73.

[174] Poon RT, Yeung C, Lo CM, Yuen WK, Liu CL, Fan ST. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc. 1999;49(5):593-8.

[175] Bordas JM, Toledo-Pimentel V, Llach J, Elena M, Mondelo F, Ginès A, et al. Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized study. Gastrointest Endosc. 1998;47(3):230-4.

[176] Schwartz JJ, Lew RJ, Ahmad NA, Shah JN, Ginsberg GG, Kochman ML, et al. The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis. Gastrointest Endosc. 2004;59(2):179-84.

[177] Talukdar R, Vege SS. Early Management of Severe Acute Pancreatitis. Curr Gastroenterol Rep 2011;13(2):123–30.

Acute Pancreatitis

Edited by Prof. Luis Rodrigo

Acute Pancreatitis (AP) in approximately 80% of cases, occurs as a secondary complication related to gallstone disease and alcohol misuse. However there are several other different causes that produce it such as metabolism, genetics, autoimmunity, post-ERCP, and trauma for example... This disease is commonly associated with the sudden onset of upper abdominal pain that is usually severe enough to warrant the patient seeking urgent medical attention. Overall, 10-25% of AP episodes are classified as severe. This leads to an associated mortality rate of 7-30% that has not changed in recent years. Treatment is conservative and generally performed by experienced teams often in ICUs. Although most cases of acute pancreatitis are uncomplicated and resolve spontaneously, the presence of complications has a significant prognostic importance. Necrosis, hemorrhage, and infection convey up to 25%, 50%, and 80% mortality, respectively. Other complications such as pseudocyst formation, pseudo-aneurysm formation, or venous thrombosis, increase morbidity and mortality to a lesser degree. The presence of pancreatic infection must be avoided.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Alejandro González-Ojeda, Carlos Dávalos-Cobian, Elizabeth Andalón-Dueñas, Mariana Chávez-Tostado, Arturo Espinosa-Partida and Clotilde Fuentes-Orozco (2012). Endoscopic Retrograde Cholangiopancreatography-Related Acute Pancreatitis – Identification, Prophylaxis and Treatment, Acute Pancreatitis, Prof. Luis Rodrigo (Ed.), ISBN: 978-953-307-984-4, InTech, Available from: http://www.intechopen.com/books/acute-pancreatitis/endoscopic-retrograde-cholangiopancreatography-related-acute-pancreatitis-identification-prophylaxis

INTECH
open science | open minds